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Abstract
Rationale: Pulmonary arterial hypertension (PAH) is a rare
progressive disease of thepulmonary vasculature that is characterized
by endothelial dysfunction, inflammation, and right ventricular
dysfunction.
Objectives: The main objective was to determine whether
endothelial, inflammatory, and cardiac biomarkers would be
associated with the World Health Organization functional
assessment and survival in patients with PAH.
Methods:We performed a retrospective cohort study of patients
with PAH enrolled in the Randomized Clinical Trial of Aspirin and
Simvastatin for Pulmonary Arterial Hypertension (ASA-STAT).
Biomarkers (N-terminal fragment of pro-BNP [NT-pro-BNP], von
Willebrand factor [vWF], soluble P selectin, C-reactive protein,
total and high-density lipoprotein cholesterol, triglycerides, tumor
necrosis factor, IL-6, b-thromboglobulin, and thromboxane B2)
were measured at baseline. Patients from the study were followed
until lung transplantation, death, orAugust 1, 2013.Ordinal logistic
regression and Cox regression analyses were performed.
Measurements andMain Results: Sixty-five patients with PAH
were enrolled. The mean age was 51 years, and 86% were women.
Higher vWF activity, lower high-density lipoprotein cholesterol,
and higher thromboxane B2 levels were associated with worseWorld
Health Organization functional class after adjustment for age, sex,
and etiology of PAH.HigherNT-pro-BNP levels, lower vWFactivity,
and lower total cholesterol were associated with an increased risk
of death or lung transplant after adjustment for age, sex, etiology of
PAH, and 6-minute-walk distance.
Conclusions: In patients with PAH, lower vWF activity and
cholesterol levels and higher NT-pro-BNP levels at baseline were
associated with an increased risk of death or transplantation.
Clinical trial registered with www.clinicaltrials.gov (NCT00384865).
Keywords: biomarkers; pulmonary arterial hypertension; World
Health Organization functional class; survival
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Pulmonary arterial hypertension (PAH) is a
rare and progressive disease of the
pulmonary vasculature that leads to exercise
limitation and eventually right ventricular
(RV) failure and death. Endothelial
dysfunction of the pulmonary vasculature is
characterized by inflammation, impaired
vasoactive balance, platelet activation, and
in situ thrombosis (1–3). Increased
afterload leads to RV strain and
dysfunction, with resultant release of
molecular mediators from the heart.
Biomarkers that reflect underlying
pathophysiologic processes as well as the
patient’s functional status would be helpful
in diagnosis, evaluation, and follow up of
patients with PAH. Several potential
biomarkers have been evaluated in PAH;
however, their usefulness in predicting
functional status and survival in PAH has
not been definitively established. Current
PAH guidelines only recommend the use of
brain natriuretic peptide (BNP) or the
N-terminal fragment of pro-BNP
(NT-pro-BNP) at diagnosis and for
longitudinal follow up of patients (4).
Markers of inflammation (IL-6, tumor
necrosis factor [TNF], and C-reactive
protein [CRP]) are increased in patients
with PAH (5–7). Markers of platelet and
endothelial dysfunction, such as von
Willebrand factor (vWF), soluble P selectin,
b-thromboglobulin (BTG), and
thromboxane B2 (TX), are also elevated in
patients with PAH (2, 8–10). Higher levels
of BNP and NT-pro-BNP, indicators of
ventricular stretch, are associated with an
increased risk of death in patients with
PAH (11, 12). Brachial artery flow-
mediated dilation (FMD) is a measure of
nitric oxide (NO)-dependent vasodilation
in response to shear stress from transient
flow restriction and is associated with
disease severity in children with idiopathic
PAH (13).
The Randomized Clinical Trial of
Aspirin and Simvastatin for Pulmonary
Arterial Hypertension (ASA-STAT) was a
multicenter randomized clinical trial of
aspirin and simvastatin in patients with PAH
with a primary end point of 6-minute-walk
distance (6MWD) at 6 months. We used the
ASA-STAT cohort to evaluate the
relationship between biomarkers of
inflammation, endothelial dysfunction,
thrombosis, and RV function with World
Health Organization (WHO) functional class
and long-term transplant-free survival in
patients with prevalent PAH. Some of the
results of these studies have been previously
reported in the form of abstracts (14, 15).
Methods
Study Design and Participants
We performed a retrospective cohort study
of patients enrolled in ASA-STAT (16).
ASA-STAT was a multicenter phase II
randomized, double-blind, placebo-
controlled 23 2 factorial study to
determine the efficacy and safety of aspirin
and simvastatin in patients with PAH
receiving background therapy. Patients
with PAH from four academic medical
centers were recruited into the trial:
Columbia University, Johns Hopkins
University, University of Pennsylvania, and
Tufts Medical Center. Patients were eligible
if they were older than 18 years of age and
without an indication (or contraindication)
for aspirin or simvastatin. Sixty-five
patients were randomized between January
2007 and September 2009, when the
study was terminated for futility in reaching
the primary end point. The trial had four
study visits over a 6-month treatment
period and three telephone follow ups.
For this analysis, patients from the study
were followed until lung transplantation,
death, or August 1, 2013. Details of the
methods have been published
elsewhere (16, 17).
The trial protocol and this study were
approved by the institutional review
board at each participating center. The trial
was registered at www.clinicaltrials.gov
before recruitment was initiated
(NCT00384865).
Study Procedures
Blood samples were collected at every study
visit using standardized methodology (17).
Patients were non per os before midnight
the night before, with only water before the
study assessment. The blood samples were
analyzed for plasma vWF, soluble P
selectin, CRP, total and HDL cholesterol,
triglycerides, NT-pro-BNP, TNF, IL-6,
BTG, and TX. Blood samples drawn at the
baseline visit were used for the analysis.
Plasma vWF was measured using an
immunoturbidimetric assay
(Diagnostica Stago, Inc., Parsippany, NJ).
Soluble P selectin was measured by an
ELISA (R&D Systems, Minneapolis, MN).
Plasma CRP was measured using a
nephelometric assay (Siemens BNII;
Siemens Healthcare Diagnostics, Plainfield,
IN). Serum lipid profile (total cholesterol,
HDL, and triglyceride) was analyzed via a
colorimetric reaction using the Ortho
Vitros Clinical Chemistry System 950IRC
(Johnson & Johnson Clinical Diagnostics,
Rochester, NY). Plasma NT-pro-BNP was
measured using a chemiluminescent
immunometric assay (Roche Elecsys 2010;
Roche Diagnostics, Indianapolis, IN). TX
was measured in serum using ELISA
(Cayman Chemical, Ann Arbor, MI). BTG
was also measured in serum using ELISA
(Asserachrom B-TG; Diagnostica Stago).
Brachial artery ultrasound was
performed on subjects at each study visit
(ultrasound was not performed at the
University of Pennsylvania Field Center).
Baseline images of the brachial artery were
acquired at rest and after a blood
pressure cuff was inflated and deflated
according to a standard protocol (17).
FMD was calculated as the maximal
percent change in brachial artery diameter
after forearm cuff release compared with
resting brachial artery diameter. The
FMD from the baseline visit was used
in the analysis.
The WHO functional classification was
assessed by one of the study physicians at
each visit, with class I defined as no
symptoms, class II as symptoms with more
than usual activity, class III as symptoms
with less than usual activity, and class IV
with symptoms at rest (18). All assessments
were made while blinded to other variables.
The WHO functional class from the
baseline visit was used in the analysis.
The 6-minute-walk test was performed
at each study visit using a standardized
protocol in accordance with the American
Thoracic Society statement (19). The total
distance walked was recorded and rounded
to the nearest meter.
The main outcome for our analysis was
transplant-free survival. Subjects were
censored at the end of follow up, which was
August 1, 2013.
Statistical Analysis
Continuous variables were expressed as
mean6 SD or median and interquartile
range. Categorical variables were
summarized by frequencies. Pearson or
Spearman correlations, as appropriate, were
calculated to assess the relationship
between baseline biomarker levels and
baseline WHO functional class and baseline
6MWD. Multivariate ordinal logistic
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regression was performed to assess the
relationship between biomarker levels and
the WHO functional class at baseline, with
adjustment for age, sex, and etiology of
PAH. The results are presented as odds
ratios (ORs) and 95% confidence intervals
(CIs). Cox regression analysis was used to
assess the relationship between biomarker
levels and transplant-free survival, with
adjustment for age, sex, etiology of PAH,
and 6MWD. All analyses were performed
using available data; no imputation was
performed. Sensitivity analyses were
performed by additionally adjusting for
warfarin use in the regression models.
R version 3.1.1 was used for all analyses
(20). The Cox regression analysis was
performed using the survival package in
R (version survival 2.37-7) (21), and
the ordinal logistic regression analysis
was performed using the MASS
package (22) in R.
Results
Sixty-five patients with PAH were enrolled
in the ASA-STAT study (Table 1). The
mean age of subjects was 516 14 years, and
86% were women. Sixty percent were
non-Hispanic white and 20% were black.
Fifty-one percent of subjects had idiopathic
PAH, and 32% had PAH associated with
systemic sclerosis or other connective
tissue diseases. Approximately two-thirds
received an endothelin receptor
antagonist, sildenafil, or a combination.
The majority of patients (78%) were
receiving anticoagulation. Subjects were
mostly classified as WHO functional class
II or III (63% and 29%, respectively). The
average 6MWD at the baseline visit
was 4336 116 m.
Follow-Up and Outcomes
The median follow-up time was 4.56 1.2
years, and there were 101,030 patient-days
of follow up. There were 17 deaths, two
lung transplants, and only one patient lost
to follow up. Transplant-free survival at
1, 3, and 5 years was 92%, 86%, and 77%,
respectively.
At baseline, higher NT-pro-BNP,
TNF, and IL-6 levels were significantly
associated with higher WHO
functional class, whereas higher HDL was
significantly associated with lower WHO
functional class (see Table E1 in the
online supplement). Similarly, higher
NT-pro-BNP, vWF, BTG, and IL-6 were
significantly associated with lower
baseline 6MWD, and lower HDL was
strongly associated with lower 6MWD.
Higher plasma vWF at baseline was
associated with a worse WHO functional
class (OR per 50% increase in vWF, 1.56;
95% CI, 1.02–2.50) after adjustment for age,
sex, and etiology of PAH (Table 2). Lower
HDL cholesterol was associated with
greater odds of having a more advanced
WHO functional class, as were increased
levels of TX (per 800-pg/ml increments).
FMD and other biomarkers were not
significantly associated with WHO
functional class after adjustment for
covariates.
Higher NT-pro-BNP levels at baseline
were associated with a greater risk of death
or transplant during the study period
(hazard ratio [HR] per 500-pg/ml increase
in NTpro-BNP, 1.13; 95% CI, 1.05–1.21;
P , 0.001) after adjustment for age, sex,
etiology of PAH, and the 6MWD
Table 1. Baseline characteristics of study subjects
Study Subjects (N = 65)
Age, yr 516 14
Female sex, n (%) 56 (86)
Body mass index, kg/m2 27.96 6.9
Race/ethnicity, n (%)
White (non-Hispanic) 39 (60)




PAH diagnosis, n (%)
Idiopathic 33 (51)
Heritable 3 (5)
Congenital systemic to pulmonary shunt 6 (9)
Systemic sclerosis 12 (18)
Other connective tissue disease 9 (14)
Drugs/toxins 2 (3)




Iloprost, inhaled 9 (14)
Sildenafil 42 (65)
Treprostinil, intravenous 5 (8)
Combination therapy 40 (62)
Warfarin 51 (78)
WHO functional classification, n (%)
Class I 5 (8)
Class II 41 (63)
Class III 19 (29)
6-min walk distance, m 4336 116
Biomarkers
NT-pro-BNP, pg/ml 204 (82–1,451)
Total cholesterol, mg/dl 1816 37
HDL cholesterol, mg/dl 506 16
vWF, % 1426 69
FMD, % (n = 56) 66 5
CRP, mg/ml 2.8 (1.1–6.3)
TNF, pg/ml (n = 62) 3.6 (1.9–6.2)
Triglycerides, mg/dl 1206 52
sP selectin, ng/ml 55.36 26.1
BTG, IU/ml 50.7 (26.7–110.4)
TX, pg/ml 1,315 (401–3,775)
IL-6, pg/ml (n = 62) 3.3 (2.1–5.5)
Definition of abbreviations: BTG = b-thromboglobulin; CRP =C-reactive protein; FMD= flow-mediated
dilation; HDL = high-density lipoprotein; NT-pro-BNP = N-terminal pro-brain natriuretic peptide;
PAH = pulmonary arterial hypertension; sP selectin = soluble P selectin; TNF = tumor necrosis
factor; TX = thromboxane B2; vWF = von Willebrand factor; WHO = World Health Organization.
Continuous variables presented as either mean6 SD or median (interquartile range). Categorical
variables presented as n (%).
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(Table 3). A 50 mg/dl lower total
cholesterol was associated with a greater
risk of death or transplant after adjustment
for the same covariates (HR, 2.35; 95% CI,
1.26–4.40; P , 0.001). A 50% absolute
decrease in vWF activity was also
associated with worse outcome (HR, 1.32;
95% CI, 1.00–1.75; P = 0.05). FMD and
other biomarkers were not associated with
transplant-free survival.
Further adjustment for warfarin use
had no impact on the effect estimates of the
associations of the biomarkers with WHO
functional class or transplant-free survival
(Tables E2 and E3).
Discussion
In a clinical trial population of patients with
PAH, lower levels of HDL cholesterol were
associated with worse functional class.
Higher levels of NT-pro-BNP and lower total
cholesterol levels were associated with
higher risk of death or lung transplantation
after adjustment for age, sex, etiology of PAH,
and the 6MWD. Although higher plasma
vWF activity was associated with worse
WHO functional class, it was also
surprisingly associated with better
transplant-free survival. FMD,
IL-6, TNF, and CRP were not associated with
WHO functional class or transplant-free
survival in adjusted analyses.
Cholesterol and lipoproteins have
recently been implicated as markers of
inflammation. Low cholesterol levels have
been associated with an increased risk of
sepsis in critically ill as well as surgical
patient populations (23, 24). Low
cholesterol levels have also been associated
with poor survival in several patient
populations, including the elderly (25) and
patients with congestive heart failure
(26–28), rheumatoid arthritis (29), and
end-stage renal disease (30, 31).
Previously, patients with PAH were found
to have lower HDL cholesterol levels than
age- and sex-matched control subjects
(32), and lower HDL cholesterol levels
were associated with worse survival
independent of other potential
confounders (33, 34). The prognostic
significance of HDL cholesterol was not
confirmed in a multicenter prospective
cohort study of incident patients with
PAH (35).
In the current study of patients with
prevalent PAH, we demonstrate an
association between low serum cholesterol
(at baseline, before administration of
simvastatin or placebo) and higher risk of
death or lung transplantation. Lower
cholesterol levels could reflect a
malnourished state in the setting of
malabsorption due to chronic bowel wall
edema and decreased hepatic synthetic
function leading to bacterial translocation
and a chronic inflammatory response
(31, 36). We also found that lower HDL
cholesterol levels were associated with
worse WHO functional class but not with
survival (33, 34). Inflammation is
believed to influence levels of cholesterol.
However, inflammatory markers were not
associated with outcomes in our study,
as they have been in other studies (7).
Our study confirms previous findings
that higher levels of NT-pro-BNP are
associated with higher risk of death or
lung transplantation (12, 37–39).
NT-pro-BNP is secreted predominantly
from ventricular tissue in response to stretch
and overload. BNP levels have been shown
to correlate with RV parameters, such as
Table 2. Relationship between biomarker levels and World Health Organization
functional class (n = 65)
Biomarker OR* 95% CI P Value
NT-pro-BNP (per 500-pg/ml increase) 1.05 0.95–3.44 0.48
vWF (per 50% increase) 1.56 1.02–2.50 0.049
Total cholesterol (per 50-mg/dl decrease) 1.49 0.74–3.06 0.27
HDL cholesterol (per 15-mg/dl decrease) 2.11 1.23–3.83 0.009
FMD (per 1% increase)† 0.99 0.89–1.09 0.78
CRP (per 1-mg/ml increase) 0.97 0.92–1.03 0.39
TNF (per 1-pg/ml increase)‡ 1.07 0.99–1.33 0.54
Triglycerides (per 50-mg/dl decrease) 0.70 0.41–1.16 0.17
sP-selectin (per 25-ng/ml increase) 0.97 0.58–1.61 0.91
BTG (per 40-IU/ml increase) 1.18 0.81–1.73 0.37
TX (per 800-pg/ml increase) 1.11 1.01–1.23 0.041
IL-6 (per 1-pg/ml increase)‡ 1.22 1.04–1.60 0.10
Definition of abbreviations: BTG = b-thromboglobulin; CI = confidence interval; CRP =C-reactive
protein; FMD= flow-mediated dilation; HDL = high-density lipoprotein; NT-pro-BNP =N-terminal pro-
brain natriuretic peptide; OR = odds ratio; sP selectin = soluble P selectin; TNF = tumor necrosis
factor; TX = thromboxane B2; vWF = von Willebrand factor
*Adjusted for age, sex and etiology of pulmonary arterial hypertension.
†n = 56.
‡n = 62.
Table 3. Relationship between biomarker levels and transplant-free survival (n = 65)
Biomarker HR* 95% CI P Value
NT-pro-BNP (per 500-pg/ml increase) 1.13 1.05–1.21 ,0.001
vWF (per 50% decrease) 1.32 1.00–1.75 0.05
Total cholesterol (per 50-mg/dl decrease) 2.35 1.26–4.40 ,0.001
HDL cholesterol (per 15-mg/dl decrease) 1.42 0.78–2.60 0.25
FMD (per 1% increase)† 0.98 0.87–1.10 0.74
CRP (per 1-mg/ml increase) 0.97 0.90–1.05 0.43
TNF (per 1-pg/ml increase)‡ 0.99 0.95–1.02 0.48
Triglycerides (per 50-mg/dl decrease) 1.16 0.75–1.78 0.51
sP-selectin (per 25-ng/ml increase) 0.86 0.53–1.41 0.56
BTG (per 40-IU/ml increase) 1.07 0.77–1.47 0.69
TX (per 800-pg/ml increase) 1.01 0.93–1.09 0.85
IL-6 (per 1-pg/ml increase)‡ 1.00 0.95–1.05 0.97
Definition of abbreviations: BTG = b-thromboglobulin; CI = confidence interval; CRP =C-reactive
protein; FMD = flow-mediated dilation; HDL = high-density lipoprotein; HR = hazard ratio; NT-pro-
BNP =N-terminal pro-brain natriuretic peptide; sP selectin = soluble P selectin; TNF = tumor necrosis
factor; TX = thromboxane B2; vWF = von Willebrand factor.
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RV ejection fraction and RV end-diastolic
pressure (12). Although BNP and
NT-pro-BNP levels have been associated
with the WHO functional class (40), we
did not find such an association in this
cohort. In patients with PAH associated
with systemic sclerosis, despite similar
hemodynamics, levels of NT-pro-BNP are
higher than in patients with idiopathic
PAH (41). The inclusion of patients with
connective tissue disease–related PAH
may account for the lack of association
between WHO functional class and
NT-pro-BNP in our study.
vWF plays a pivotal role in homeostasis
and thrombogenesis by initiating platelet
adhesion and aggregation and stabilizing
factor VIII. Higher vWF activity has been
associated with worse survival in patients
with PAH (9, 42–44). In the current study,
lower vWF activity was associated with
worse survival and/or need for lung
transplantation, and these results were
independent of warfarin use. One possible
explanation is that in a cohort of patients
receiving background PAH therapy,
persistently low vWF activity may reflect a
state of persistent shear stress–induced
proteolysis of vWF that did not improve
with PAH treatment (45). Low vWF
activity perhaps indicates ongoing
endothelial perturbation in patients with
more severe PAH, portending worse
survival. vWF has also been shown to be a
potent angiogenesis inhibitor (46). It is
possible that in the presence of low vWF
activity there is increased angiogenesis
leading to a more aggressive PAH
phenotype and worse survival.
FMD impairment is believed to
result from a decrease in the activity of
the L-arginine–NO synthetic pathway and
increased NO degradation in vascular
smooth muscle cells (47, 48). A reflection of
endothelial function, brachial artery FMD
is associated with cardiac index and RV
performance in children with idiopathic
PAH (13) and with pulmonary
vasoreactivity in adults with idiopathic
PAH (49). Brachial artery FMD is also
associated with increased mortality in
patients with congestive heart failure (50).
In the current study, FMD was not
associated with WHO functional class or
transplant-free survival.
Our study has several strengths,
including the prospective and multicenter
design, rigorous standardized blood
collection and analysis procedures with
blinding to other information, and near
complete long-term follow up. There are
some limitations, however. The study
sample was drawn from a clinical trial (with
several inclusion/exclusion criteria), so
that the findings may not be generalizable to
the larger population of patients with PAH.
In addition, biomarkers were assessed
while on background PAH-specific therapy
in a prevalent (rather than incident)
population. We are therefore unable to
speculate whether the associations we found
would hold at the time of diagnosis before
initiation of PAH-specific therapy. The
study was designed and powered to detect a
difference in the 6MWD between the active
treatment groups and placebo; the results
should be interpreted in the context of
hypothesis generation. Although the small
number of events provides limited power,
the lack of association between some of the
biomarkers and outcome is supported by
effect estimates close to the null value with
reasonably narrow 95% CIs.
Conclusions
In the ASA-STAT study, lower vWF activity
and cholesterol levels and higher
NT-pro-BNP levels at baseline were
associated with increased risk of death or
transplantation in patients with PAH. FMD
was not associated with functional class
or transplant-free survival. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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